6-methyl-N-(1H-tetrazol-5-yl)-2-pyridinecarboxamide: RN & structure given in first source; RN not in Chemline 3/84 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 54982 |
| SCHEMBL ID | 17041897 |
| MeSH ID | M0120226 |
| Synonym |
|---|
| 6-methyl-n-tetrazol-5-yl-2-pyridinecarboxamide |
| 6-methyl-n-(1h-tetrazol-5-yl)-2-pyridinecarboxamide |
| 2-pyridinecarboxamide, 6-methyl-n-tetrazol-5-yl- |
| brn 3614749 |
| ta 5707f |
| 6-methyl-n-(5h-tetrazol-5-yl)pyridine-2-carboxamide |
| 83282-08-0 |
| unii-b4pervzim7 |
| SCHEMBL17041897 |
| DTXSID801003255 |
| 6-methyl-n-(5h-tetrazol-5-yl)pyridine-2-carboximidic acid |
| PD160031 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " In dogs the in vivo absorption rate was similar to the in vitro dissolution rate, but in humans it was only about half." | ( Preparation of controlled release granules of TA-5707F using enteric polymers and ethylcellulose, and their in vivo evaluation. Maejima, T; Matsukawa, Y; Osawa, T; Yamakita, H, 1996) | 0.29 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "Studies on controlled release dosage forms were conducted by using waxy materials for a newly developed anti-allergy drug, 6-methyl-N-(1H-tetrazol-5-yl)-2-pyridinecarboxamide (TA-5707F), which is not maintained at an effective level in blood for a long duration." | ( Preparation of controlled release tablets of TA-5707F with wax matrix type and their in vivo evaluation in beagle dogs. Maejima, T; Osawa, T; Yamakita, H, 1995) | 0.5 |
| "Two types of multiple controlled release dosage forms, hydroxypropylmethyl cellulose acetyl succinate (HPMC-AS) coated granules and double layer coated granules with HPMC-AS and ethyl cellulose (EC), were prepared for the newly developed antihistaminergic drug, TA-5707F, using a centrifugal fluidizing granulator." | ( Preparation of controlled release granules of TA-5707F using enteric polymers and ethylcellulose, and their in vivo evaluation. Maejima, T; Matsukawa, Y; Osawa, T; Yamakita, H, 1996) | 0.29 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.25) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (33.33%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||